A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31611281.
- Also identified by DOI 10.1158/1078-0432.CCR-19-2861.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The clinical utility of performing tumor genetic testing to assess for alterations beyond the known targetable oncogenes in lung adenocarcinoma is unclear. Analyzing cancer pathway alterations beyond single oncogenic driver mutations in addition to markers of tumor mutation burden and genomic instability may provide additional predictive and prognostic information.<i>See related article by Zhou et al., p. 7475</i>.
Medical subject headings
- Adenocarcinoma of Lung
- Lung Neoplasms